Obstetrics Flashcards
Abdominal pain in pregnancy
Abdominal pain in pregnancy may be divided into causes which occur early, late or at any point.
Early pregnancy
Cause
Notes
Ectopic pregnancy
This is the single most important cause of abdominal pain to exclude in early pregnancy
0.5% of all pregnancies are ectopic
Risk factors (anything slowing the ovum’s passage to the uterus)
damage to tubes (salpingitis, surgery)
previous ectopic
IVF (3% of pregnancies are ectopic)
A typical history is a female with a history of 6-8 weeks amenorrhoea who presents with lower abdominal pain and later develops vaginal bleeding
lower abdominal pain: typically the first symptom. Pain is usually constant and may be unilateral. Due to tubal spasm
vaginal bleeding: usually less than a normal period, may be dark brown in colour
history of recent amenorrhoea: typically 6-8 weeks from start of last period; if longer (e.g. 10 wks) this suggest another causes e.g. inevitable abortion
peritoneal bleeding can cause shoulder tip pain and pain on defecation / urination
Miscarriage
Threatened miscarriage
painless vaginal bleeding occurring before 24 weeks, but typically occurs at 6 - 9 weeks
cervical os is closed
complicates up to 25% of all pregnancies
Missed (delayed) miscarriage
a gestational sac which contains a dead fetus before 20 weeks without the symptoms of expulsion
mother may have light vaginal bleeding / discharge and the symptoms of pregnancy which disappear
when the gestational sac is > 25 mm and no embryonic/fetal part can be seen it is sometimes described as a ‘blighted ovum’ or ‘anembryonic pregnancy’
Inevitable miscarriage
cervical os is open
heavy bleeding with clots and pain
Incomplete miscarriage
not all products of conception have been expelled
Late pregnancy
Cause
Notes
Labour
Regular tightening of the abdomen which may be painful in the later stages
Placental abruption
Placental abruption describes separation of a normally sited placenta from the uterine wall, resulting in maternal haemorrhage into the intervening space
Occurs in approximately 1/200 pregnancies
Clinical features
shock out of keeping with visible loss
pain constant
tender, tense uterus
normal lie and presentation
fetal heart: absent/distressed
coagulation problems
beware pre-eclampsia, DIC, anuria
Symphysis pubis dysfunction
Ligament laxity increases in response to hormonal changes of pregnancy
Pain over the pubic symphysis with radiation to the groins and the medial aspects of the thighs. A waddling gait may be seen
Pre-eclampsia/HELLP syndrome
Associated with hypertension, proteinuria. Patients with HELLP also have haemolysis, elevated liver enzymes and a low platelet count.
The pain is typically epigastric or in the RUQ
Uterine rupture
Ruptures usually occur during labour but occur in third trimester
Risk factors: previous caesarean section
Presents with maternal shock, abdominal pain and vaginal bleeding to varying degree
Any point in pregnancy
Cause
Notes
Appendicitis
Occurs in 1:1,000-2:1,000 pregnancies, making it the most common non-obstetric surgical emergency
Higher morbidity and mortality in pregnancy
Location of pain changes depending on gestation, moving up from the RLQ in the first trimester to the umbilicus in the second and the RUQ in the third
Urinary tract infection (UTI)
1 in 25 women develop in UTI in pregnancy
Associated with an increased risk of pre-term delivery and IUGR
Antenatal care: timetable
NICE issued guidelines on routine care for the healthy pregnant woman in March 2008. They recommend:
10 antenatal visits in the first pregnancy if uncomplicated
7 antenatal visits in subsequent pregnancies if uncomplicated
women do not need to be seen by a consultant if the pregnancy is uncomplicated
Gestation
Purpose of visit
8 - 12 weeks (ideally < 10 weeks)
Booking visit
general information e.g. diet, alcohol, smoking, folic acid, vitamin D, antenatal classes
BP, urine dipstick, check BMI
Booking bloods/urine
FBC, blood group, rhesus status, red cell alloantibodies, haemoglobinopathies
hepatitis B, syphilis, rubella
HIV test is offered to all women
urine culture to detect asymptomatic bacteriuria
10 - 13+6 weeks
Early scan to confirm dates, exclude multiple pregnancy
11 - 13+6 weeks
Down’s syndrome screening including nuchal scan
16 weeks
Information on the anomaly and the blood results. If Hb < 11 g/dl consider iron
Routine care: BP and urine dipstick
18 - 20+6 weeks
Anomaly scan
25 weeks (only if primip)
Routine care: BP, urine dipstick, symphysis-fundal height (SFH)
28 weeks
Routine care: BP, urine dipstick, SFH
Second screen for anaemia and atypical red cell alloantibodies. If Hb < 10.5 g/dl consider iron
First dose of anti-D prophylaxis to rhesus negative women
31 weeks (only if primip)
Routine care as above
34 weeks
Routine care as above
Second dose of anti-D prophylaxis to rhesus negative women*
Information on labour and birth plan
36 weeks
Routine care as above
Check presentation - offer external cephalic version if indicated
Information on breast feeding, vitamin K, ‘baby-blues’
38 weeks
Routine care as above
40 weeks (only if primip)
Routine care as above
Discussion about options for prolonged pregnancy
41 weeks
Routine care as above
Discuss labour plans and possibility of induction
*the evidence base suggests that there is little difference in the efficacy of single-dose (at 28 weeks) and double-dose regimes (at 28 & 34 weeks). For this reason the RCOG in 2011 advised that either regime could be used ‘depending on local factors’
For each of the following components of routine antenatal care select the gestation when it should occur
Antenatal care: specific points
NICE issued guidelines on routine care for the healthy pregnant woman in March 2008
Nausea and vomiting
natural remedies - ginger and acupuncture on the ‘p6’ point (by the wrist) are recommended by NICE
antihistamines should be used first-line (BNF suggests promethazine as first-line)
Vitamin D
NICE recommend ‘All women should be informed at the booking appointment about the importance for their own and their baby’s health of maintaining adequate vitamin D stores during pregnancy and whilst breastfeeding’
‘women may choose to take 10 micrograms of vitamin D per day, as found in the Healthy Start multivitamin supplement’. This was confirmed in 2012 when the Chief Medical Officer advised: ‘All pregnant and breastfeeding women should take a daily supplement containing 10micrograms of vitamin D, to ensure the mothers requirements for vitamin D are met and to build adequate fetal stores for early infancy’
particular care should be taken with women at risk (e.g. Asian, obese, poor diet)
Alcohol
in 2016 the Chief Medical Officer proposed new guidelines in relation to the safe consumption of alcohol following an expert group report.
the government now recommend pregnant women should not drink. The wording of the official advice is ‘If you are pregnant or planning a pregnancy, the safest approach is not to drink alcohol at all, to keep risks to your baby to a minimum. Drinking in pregnancy can lead to long-term harm to the baby, with the more you drink the greater the risk.’
Bleeding in pregnancy
The table below outlines the major causes of bleeding during pregnancy. Antepartum haemorrhage is defined as bleeding after 24 weeks
1st trimester
Spontaneous abortion
Ectopic pregnancy
Hydatidiform mole
2nd trimester
Spontaneous abortion
Hydatidiform mole
Placental abruption
3rd trimester
Bloody show
Placental abruption
Placenta praevia
Vasa praevia
Alongside the pregnancy related causes, conditions such as sexually transmitted infections and cervical polyps should be excluded.
The table below outlines the key features of each condition:
Spontaneous abortion
Threatened miscarriage - painless vaginal bleeding typically around 6-9 weeks
Missed (delayed) miscarriage - light vaginal bleeding and symptoms of pregnancy disappear
Inevitable miscarriage - complete or incomplete depending or whether all fetal and placental tissue has been expelled. Incomplete miscarriage - heavy bleeding and crampy, lower abdo pain. Complete miscarriage - little bleeding
Ectopic pregnancy
Typically history of 6-8 weeks amenorrhoea with lower abdominal pain (usually unilateral) initially and vaginal bleeding later. Shoulder tip pain and cervical excitation may be present
Hydatidiform mole
Typically bleeding in first or early second trimester associated with exaggerated symptoms of pregnancy e.g. hyperemesis. The uterus may be large for dates and serum hCG is very high
Placental abruption
Constant lower abdominal pain and, woman may be more shocked than is expected by visible blood loss. Tender, tense uterus* with normal lie and presentation. Fetal heart may be distressed
Placental praevia
Vaginal bleeding, no pain. Non-tender uterus* but lie and presentation may be abnormal
Vasa praevia
Rupture of membranes followed immediately by vaginal bleeding. Fetal bradycardia is classically seen
*vaginal examination should not be performed in primary care for suspected antepartum haemorrhage - women with placenta praevia may haemorrhage
Chorioamnionitis
Chorioamnionitis (which can affect up to 5% of all pregnancies) is a potentially life-threatening condition to both mother and foetus and is therefore considered a medical emergency. It is usually the result of an ascending bacterial infection of the amniotic fluid / membranes / placenta. The major risk factor in this scenario is the preterm premature rupture of membranes (however, it can still occur when the membranes are still intact) which expose the normally sterile environment of the uterus to potential pathogens. Prompt delivery of the foetus (via cesarean section if necessary) and administration of intravenous antibiotics is widely considered the mainstay of initial treatment for this condition.
Breastfeeding problems
‘Minor’ breastfeeding problems
frequent feeding in a breastfed infant is not alone a sign of low milk supply
nipple pain: may be caused by a poor latch
blocked duct (‘milk bleb’): causes nipple pain when breastfeeding. Breastfeeding should continue. Advice should be sought regarding the positioning of the baby. Breast massage may also be tried
nipple candidiasis: treatment for nipple candidiasis whilst breastfeeding should involve miconazole cream for the mother and nystatin suspension for the baby
Mastitis
Mastitis affects around 1 in 10 breastfeeding women. The BNF advises to treat ‘if systemically unwell, if nipple fissure present, if symptoms do not improve after 12-24 hours of effective milk removal of if culture indicates infection’. The first-line antibiotic is flucloxacillin for 10-14 days. Breastfeeding or expressing should continue during treatment.
If left untreated, mastitis may develop into a breast abscess. This generally requires incision and drainage.
Engorgement
Breast engorgement is one of the causes of breast pain in breastfeeding women. It usually occurs in the first few days after the infant is born and almost always affects both breasts. The pain or discomfort is typically worse just before a feed. Milk tends to not flow well from an engorged breast and the infant may find it difficult to attach and suckle. Fever may be present but usually settles within 24 hours. The breasts may appear red. Complications include blocked milk ducts, mastitis and difficulties with breastfeeding and, subsequently, milk supply.
Although it may initially be painful, hand expression of milk may help relieve the discomfort of engorgement.
Raynaud’s disease of the nipple
In Raynaud’s disease of the nipple, pain is often intermittent and present during and immediately after feeding. Blanching of the nipple may be followed by cyanosis and/or erythema. Nipple pain resolves when nipples return to normal colour.
Options of treatment for Raynaud’s disease of the nipple include advice on minimising exposure to cold, use of heat packs following a breastfeed, avoiding caffeine and stopping smoking. If symptoms persist consider specialist referral for a trial of oral nifedipine (off-license).
Breastfeeding: contraindications
The major breastfeeding contraindications tested in exams relate to drugs (see below). Other contraindications of note include:
galactosaemia
viral infections - this is controversial with respect to HIV in the developing world. This is because there is such an increased infant mortality and morbidity associated with bottle feeding that some doctors think the benefits outweigh the risk of HIV transmission
Drug contraindications
The following drugs can be given to mothers who are breastfeeding:
antibiotics: penicillins, cephalosporins, trimethoprim
endocrine: glucocorticoids (avoid high doses), levothyroxine*
epilepsy: sodium valproate, carbamazepine
asthma: salbutamol, theophyllines
psychiatric drugs: tricyclic antidepressants, antipsychotics**
hypertension: beta-blockers, hydralazine
anticoagulants: warfarin, heparin,
digoxin
The following drugs should be avoided:
antibiotics: ciprofloxacin, tetracycline, chloramphenicol, sulphonamides
psychiatric drugs: lithium, benzodiazepines
aspirin
carbimazole
methotrexate
sulfonylureas
cytotoxic drugs
amiodarone
*the BNF advises that the amount is too small to affect neonatal hypothyroidism screening
**clozapine should be avoided
Breech presentation
In a breech presentation the caudal end of the fetus occupies the lower segment. Whilst around 25% of pregnancies at 28 weeks are breech it only occurs in 3% of babies near term. A frank breech is the most common presentation with the hips flexed and knees fully extended. A footling breech, where one or both feet come first with the bottom at a higher position, is rare but carries a higher perinatal morbidity
Risk factors for breech presentation
uterine malformations, fibroids
placenta praevia
polyhydramnios or oligohydramnios
fetal abnormality (e.g. CNS malformation, chromosomal disorders)
prematurity (due to increased incidence earlier in gestation)
Cord prolapse is more common in breech presentations
Management
if < 36 weeks: many fetuses will turn spontaneously
if still breech at 36 weeks NICE recommend external cephalic version (ECV)- this has a success rate of around 60%. The RCOG recommend ECV should be offered from 36 weeks in nulliparous women and from 37 weeks in multiparous women
if the baby is still breech then delivery options include planned caesarean section or vaginal delivery
Information to help decision making - the RCOG recommend:
‘Women should be informed that planned caesarean section carries a reduced perinatal mortality and early neonatal morbidity for babies with a breech presentation at term compared with planned vaginal birth.’
‘Women should be informed that there is no evidence that the long term health of babies with a breech presentation delivered at term is influenced by how the baby is born.’
RCOG absolute contraindications to ECV:
where caesarean delivery is required
antepartum haemorrhage within the last 7 days
abnormal cardiotocography
major uterine anomaly
ruptured membranes
multiple pregnancy
Chickenpox exposure in pregnancy
Chickenpox is caused by primary infection with varicella-zoster virus. Shingles is caused by the reactivation of dormant virus in dorsal root ganglion. In pregnancy, there is a risk to both the mother and also the fetus, a syndrome now termed fetal varicella syndrome
Risks to the mother
5 times greater risk of pneumonitis
Fetal varicella syndrome (FVS)
risk of FVS following maternal varicella exposure is around 1% if occurs before 20 weeks gestation
studies have shown a very small number of cases occurring between 20-28 weeks gestation and none following 28 weeks
features of FVS include skin scarring, eye defects (microphthalmia), limb hypoplasia, microcephaly and learning disabilities
Other risks to the fetus
shingles in infancy: 1-2% risk if maternal exposure in the second or third trimester
severe neonatal varicella: if the mother develops rash between 5 days before and 2 days after birth there is a risk of neonatal varicella, which may be fatal to the newborn child in around 20% of cases
Management of chickenpox exposure
if there is any doubt about the mother previously having chickenpox maternal blood should be urgently checked for varicella antibodies
if the pregnant women is not immune to varicella she should be given varicella-zoster immunoglobulin (VZIG) as soon as possible. RCOG and Greenbook guidelines suggest VZIG is effective up to 10 days post exposure
consensus guidelines suggest oral aciclovir should be given if pregnant women with chickenpox present within 24 hours of onset of the rash
When contact occurs with chickenpox or shingles, it is paramount to take a detailed clinical history to confirm the significance of the contact and susceptibility of the patient.
Significant contact is defined as face-to-face contact, being in the same room for more than 15 minutes or contact in the setting of a large open ward.
The susceptibility of the woman should be determined by eliciting a past medical history of chickenpox or shingles. If there is a definite past medical history of chickenpox, it is reasonable to assume that she is immune to the varicella infection and no further action is required.
If there is no clear history of previous chickenpox, or she is from a tropical or subtropical area then serological testing for varicella-zoster virus IgG would be required.
Individuals born or raised in tropical climates are less likely to be immune to varicella and a history of chickenpox can be a less reliable predictor of immunity within this population.
RCOG Greentop guidelines, Chickenpox in pregnancy.
Eclampsia
Eclampsia may be defined as the development of seizures in association pre-eclampsia. To recap, pre-eclampsia is defined as:
condition seen after 20 weeks gestation
pregnancy-induced hypertension
proteinuria
Magnesium sulphate is used to both prevent seizures in patients with severe pre-eclampsia and treat seizures once they develop. Guidelines on its use suggest the following:
should be given once a decision to deliver has been made
in eclampsia an IV bolus of 4g over 5-10 minutes should be given followed by an infusion of 1g / hour
urine output, reflexes, respiratory rate and oxygen saturations should be monitored during treatment
respiratory depression can occur: calcium gluconate is the first-line treatment for magnesium sulphate induced respiratory depression
treatment should continue for 24 hours after last seizure or delivery (around 40% of seizures occur post-partum)
Other important aspects of treating severe pre-eclampsia/eclampsia include fluid restriction to avoid the potentially serious consequences of fluid overload
Epilepsy pregnancy and breast feeding
The risks of uncontrolled epilepsy during pregnancy generally outweigh the risks of medication to the fetus. All women thinking about becoming pregnant should be advised to take folic acid 5mg per day well before pregnancy to minimise the risk of neural tube defects. Around 1-2% of newborns born to non-epileptic mothers have congenital defects. This rises to 3-4% if the mother takes antiepileptic medication.
Other points
aim for monotherapy
there is no indication to monitor antiepileptic drug levels
sodium valproate: associated with neural tube defects
carbamazepine: often considered the least teratogenic of the older antiepileptics
phenytoin: associated with cleft palate
lamotrigine: studies to date suggest the rate of congenital malformations may be low. The dose of lamotrigine may need to be increased in pregnancy
Breast feeding is generally considered safe for mothers taking antiepileptics with the possible exception of the barbiturates
It is advised that pregnant women taking phenytoin are given vitamin K in the last month of pregnancy to prevent clotting disorders in the newborn
Sodium valproate
The November 2013 issue of the Drug Safety Update also carried a warning about new evidence showing a significant risk of neurodevelopmental delay in children following maternal use of sodium valproate.
The update concludes that sodium valproate should not be used during pregnancy and in women of childbearing age unless clearly necessary. Women of childbearing age should not start treatment without specialist neurological or psychiatric advice.
Breast feeding is acceptable with nearly all anti-epileptic drugs
Importance: 99
The BNF states ‘breast-feeding is acceptable with all antiepileptic drugs, taken in normal doses, with the possible exception of barbiturates’
Anti-epileptics in pregnancy can be a tricky subject. Many are known to cause severe congenital defects (both structural and intellectual) and as such the first line of care is good contraceptive advice and planning with the patient in question. This is however, not always possible and there will always be cases where a patient becomes pregnant whilst on anti-epileptic medication prior to consulting with a doctor.
The recent MBRRACE-UK and the NICE clinical guidelines both state that most women with epilepsy and of child bearing age are currently prescribed lamotrigine and during pregnancy this may require a dose increase. Phenytoin, phenobarbitone and sodium valproate are all known to have an adverse effect on cognitive abilities and therefore are usually avoided unless absolutely necessary.
Lamotrigine, carbamazepine and levetiracetam are known to have the smallest effects on the developing foetus, however all epileptics who are either pregnant or are planning to become pregnant should be referred to specialist care as soon as possible.
Folic acid
Folic acid is converted to tetrahydrofolate (THF). Green, leafy vegetables are a good source of folic acid.
Functions
THF plays a key role in the transfer of 1-carbon units (e.g. methyl, methylene, and formyl groups) to the essential substrates involved in the synthesis of DNA & RNA
Causes of folic acid deficiency:
phenytoin
methotrexate
pregnancy
alcohol excess
Consequences of folic acid deficiency:
macrocytic, megaloblastic anaemia
neural tube defects
Prevention of neural tube defects (NTD) during pregnancy:
all women should take 400mcg of folic acid until the 12th week of pregnancy
women at higher risk of conceiving a child with a NTD should take 5mg of folic acid from before conception until the 12th week of pregnancy
women are considered higher risk if any of the following apply:
→ either partner has a NTD, they have had a previous pregnancy affected by a NTD, or they have a family history of a NTD
→ the woman is taking antiepileptic drugs or has coeliac disease, diabetes, or thalassaemia trait.
→ the woman is obese (defined as a body mass index [BMI] of 30 kg/m2 or more).
Folic acid is important to prevent neural tube defects in the foetus. Currently it is recommended that all women who are planning to become pregnant should take a supplement of 400 micrograms of folic acid per day whilst trying to conceive and once pregnancy, they should continue taking this dose until the 12th week of pregnancy.
In cases where there has been a previous pregnancy affected by neural tube defects or if there is a family history, this dose should be increased to 5 milligrams, however in the case of this patient there is no history and therefore 400 micrograms is recommended.
Women are advised to take folic acid 400mcg when trying to conceive through to 12 weeks gestation to reduce the incidence of neural tube defects. A higher dose of 5mg is indicated if there are additional risk factors eg. diabetes or personal or family history of neural tube defects. A daily supplement of vitamin D 10mcg is also advised throughout pregnancy for bone health, and should be continued for the duration of breastfeeding. If a woman chooses to take a multivitamin in pregnancy, she should be advised to ensure it does not contain vitamin A (retinol) as it is teratogenic in high doses.
Source: NHS Choices
http://www.nhs.uk/conditions/pregnancy-and-baby/pages/vitamins-minerals-supplements-pregnant.aspx#close
Gestational trophoblastic disorders
Describes a spectrum of disorders originating from the placental trophoblast:
complete hydatidiform mole
partial hydatidiform mole
choriocarcinoma
Complete hydatidiform mole
Benign tumour of trophoblastic material. Occurs when an empty egg is fertilized by a single sperm that then duplicates its own DNA, hence the all 46 chromosomes are of paternal origin
Features
bleeding in first or early second trimester
exaggerated symptoms of pregnancy e.g. hyperemesis
uterus large for dates
very high serum levels of human chorionic gonadotropin (hCG)
hypertension and hyperthyroidism* may be seen
Management
urgent referral to specialist centre - evacuation of the uterus is performed
effective contraception is recommended to avoid pregnancy in the next 12 months
Around 2-3% go on to develop choriocarcinoma
In a partial mole a normal haploid egg may be fertilized by two sperms, or by one sperm with duplication of the paternal chromosomes. Therefore the DNA is both maternal and paternal in origin. Usually triploid - e.g. 69 XXX or 69 XXY. Fetal parts may be seen
*hCG can mimic thyroid-stimulating hormone (TSH)
Group B Streptococcus
GBS is a vaginal commensal isolated in many women. It is known to be the most frequent cause of severe early-onset infection in the newborn and can cause significant morbidity and mortality.
If it is isolated during the antenatal period, it does not require treatment immediately, as it will not reduce the likelihood of colonisation at delivery.
However, intrapartum intravenous benzylpenicillin is required to reduce neonatal transmission. An alternative would be clindamycin. This applies to GBS isolated in vaginal swabs and urine. (GBS urinary tract infection in pregnancy requires appropriate antibiotics at the time also).
There is no screening programme in the UK for GBS, vaginal swabs should be taken only when clinically indicted. Women who have had a previous baby infected with GBS are also offered intrapartum intravenous benzylpenicillin in future pregnancies.
Group B Streptococcus (GBS) is the most common cause of early-onset severe infection in the neonatal period. It is thought around 20-40% of mothers have GBS present in their bowel flora and may therefore be thought of as ‘carriers’ of GBS. Infants may be exposed to maternal GBS during labour and subsequently develop potentially serious infections.
Risk factors for Group B Streptococcus (GBS) infection:
prematurity
prolonged rupture of the membranes
previous sibling GBS infection
maternal pyrexia e.g. secondary to chorioamnionitis
Management
The Royal College of Obstetricians and Gynaecologists (RCOG) published guidelines on GBS in 2017.
The main points are as follows:
universal screening for GBS should not be offered to all women
the guidelines also state a maternal request is not an indication for screening
women who’ve had GBS detected in a previous pregnancy should be informed that their risk of maternal GBS carriage in this pregnancy is 50%. They should be offered maternal intravenous antibiotic prophylaxis (IAP) OR testing in late pregnancy and then antibiotics if still positive
if women are to have swabs for GBS this should be offered at 35-37 weeks or 3-5 weeks prior to the anticipated delivery date
maternal intravenous antibiotic prophylaxis should be offered to women with a previous baby with early- or late-onset GBS disease
maternal intravenous antibiotic prophylaxis should be offered to women in preterm labour regardless of their GBS status
women with a pyrexia during labour (>38ºC) should also be given intravenous antibiotics
benzylpenicillin is the antibiotic of choice for GBS prophylaxis
Group B streptococcus (GBS) bacteriuria is associated with an increased risk of chorioamnionitis and neonatal sepsis. The Royal College of Obstetricians and Gynaecologists states that women with GBS bacteriuria should therefore be offered intrapartum antibiotics in addition to appropriate treatment at the time of diagnosis. For non-penicillin-allergic patients intrapartum antibiotics will consist of intravenous benzylpenicillin given as soon as possible after the start of labour, then at 4-hourly intervals until delivery.
Postnatal antibiotic treatment is not indicated unless there are signs of neonatal infection. Caesarean section is not indicated.
HIV and pregnancy
With the increased incidence of HIV infection amongst the heterosexual population there are an increasing number of HIV positive women giving birth in the UK. In London the incidence may be as high as 0.4% of pregnant women. The aim of treating HIV positive women during pregnancy is to minimise harm to both the mother and fetus, and to reduce the chance of vertical transmission.
Guidelines regularly change on this subject and most recent guidelines can be found using the links provided.
Factors which reduce vertical transmission (from 25-30% to 2%)
maternal antiretroviral therapy
mode of delivery (caesarean section)
neonatal antiretroviral therapy
infant feeding (bottle feeding)
Screening
NICE guidelines recommend offering HIV screening to all pregnant women
Antiretroviral therapy
all pregnant women should be offered antiretroviral therapy regardless of whether they were taking it previously
Mode of delivery
vaginal delivery is recommended if viral load is less than 50 copies/ml at 36 weeks, otherwise caesarian section is recommended
a zidovudine infusion should be started four hours before beginning the caesarean section
Neonatal antiretroviral therapy
zidovudine is usually administered orally to the neonate if maternal viral load is <50 copies/ml. Otherwise triple ART should be used. Therapy should be continued for 4-6 weeks.
Infant feeding
In the UK all HIV positive women should be advised not to breastfeed
In the UK all HIV positive women should be advised not to breastfeed, hence only option 2 is correct. It is not advisable to breastfeed regardless of the viral load, the amount of breastfeeding or whether she or the baby is on the antiretroviral therapy.
Hypertension in pregnancy
NICE published guidance in 2010 on the management of hypertension in pregnancy. They also made recommendations on reducing the risk of hypertensive disorders developing in the first place. Women who are at high risk of developing pre-eclampsia should take aspirin 75mg od from 12 weeks until the birth of the baby. High risk groups include:
hypertensive disease during previous pregnancies
chronic kidney disease
autoimmune disorders such as SLE or antiphospholipid syndrome
type 1 or 2 diabetes mellitus
The classification of hypertension in pregnancy is complicated and varies. Remember, in normal pregnancy:
blood pressure usually falls in the first trimester (particularly the diastolic), and continues to fall until 20-24 weeks
after this time the blood pressure usually increases to pre-pregnancy levels by term
Hypertension in pregnancy in usually defined as:
systolic > 140 mmHg or diastolic > 90 mmHg
or an increase above booking readings of > 30 mmHg systolic or > 15 mmHg diastolic
After establishing that the patient is hypertensive they should be categorised into one of the following groups
Pre-existing hypertension
Pregnancy-induced hypertension
(PIH, also known as gestational hypertension)
Pre-eclampsia
A history of hypertension before pregnancy or an elevated blood pressure > 140/90 mmHg before 20 weeks gestation
No proteinuria, no oedema
Occurs in 3-5% of pregnancies and is more common in older women
Hypertension (as defined above) occurring in the second half of pregnancy (i.e. after 20 weeks)
No proteinuria, no oedema
Occurs in around 5-7% of pregnancies
Resolves following birth (typically after one month). Women with PIH are at increased risk of future pre-eclampsia or hypertension later in life
Pregnancy-induced hypertension in association with proteinuria (> 0.3g / 24 hours)
Oedema may occur but is now less commonly used as a criteria
Occurs in around 5% of pregnancies
The following question tests the understanding of secondary prevention of women with pre-eclampsia. There is A level data showing that low-dose aspirin started at 12-14 weeks’ gestation is more effective than placebo at reducing occurrence of pre-eclampsia in women at high risk, reducing perinatal mortality and reducing the risk of babies being born small for gestational age . There is some evidence that low molecular weight heparin might reduce the placental insufficiency seen in pre-eclampsia, but long-term safety studies are not yet available. Labetalol and methyldopa are both common antihypertensive drugs used in the acute management of pre-eclampsia, however are not given prophylactically and do not reduce intrauterine growth retardation. Similarly to LMWH, unfractionated heparin has not been proven to prevent the development uteroplacental insufficiency.
Even though the patient is asymptomatic, she has a raised blood pressure above 160/100 mmHg combined with the significant proteinuria. Furthermore, this is despite receiving labetalol treatment. She will need emergency admission for monitoring and management of the hypertension in a controlled environment, with delivery being an option if there is no improvement.
Calcium channel blockers and ACE inhibitors, including ramipril, are teratogenic. The most widely used anti-hypertensive for pregnant women is labetalol. NICE recommend labetalol as first-line treatment in moderate and severe gestational hypertension rather than methyldopa. NICE CG107
This patient is suffering from pre-eclampsia. The National Institute for Health and Care Excellence state that women with severe hypertension in pregnancy (160/110mmHg or higher) should be treated with labetalol as first time treatment. Delivery should not be offered to women before 34 weeks unless:
severe hypertension remains refractory to treatment
maternal or fetal indications develop as specified in the consultant plan
At 34 weeks delivery should be offered to women with pre-eclampsia once a course of corticosteroids has been completed.
Intravenous magnesium sulphate can be used in the critical care setting when a woman who has severe hypertension or severe pre-eclampsia has previously had an eclamptic fit. It is not used to solely lower blood pressure.
Frusemide should not be used to treat hypertension in pregnancy because placental perfusion may be reduced and it crosses the placental barrier.
Reference:
NICE: Hypertension in pregnancy: The management of hypertensive disorders during pregnancy. https://www.nice.org.uk/guidance/cg107/chapter/1-Guidance#medical-management-of-severe-hypertension-or-severe-pre-eclampsia-in-a-critical-care-setting
The first line medication for hypertension in pregnancy is labetalol. Methyldopa can also be used but this is not recommended as first line as it is associated with an increased likelihood of postnatal depression.
Ramipril, irbesartan and bendroflumethiazide are teratogenic and therefore should not be given in pregnancy.
